The Osny business provides current good manufacturing practices development and manufacturing services for hormonal and other high potent drugs in oral dose forms that are either approved for commercial marketing or in clinical development.
The business expects to retain all employees associated with the business as of the closing, and to continue to serve all existing customers of the business. The business will become known as ‘Osny Pharma SAS’ effective as of the closing.
Hans Magnus Andresen, managing director of Bavaria, said: “Bavaria is extremely excited about this acquisition. We have been very impressed by the management and operating teams in Osny and look forward to playing a vital part in the continuation of the site’s positive development.
“The site will focus strongly on keeping its loyal customer base satisfied and continuously optimize its production processes without losing its keen eye on delivering top quality products. Osny Pharma SAS has long standing traditions in this industry and is ideally positioned for continued growth – organically as well as through additional acquisitions.”